Literature DB >> 28944168

Normalizing Tumoral Vessels to Treat Cancer: An Out-of-the-Box Strategy Involving TIE2 Pathway.

Juan Fueyo1,2, Mohammad B Hossain1, Teresa Nguyen1,3, Candelaria Gomez-Manzano1,4.   

Abstract

Entities:  

Year:  2017        PMID： 28944168      PMCID： PMC5608255          DOI： 10.21037/tcr.2017.03.64

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  30 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

Review 3.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

4.  Bevacizumab in glioblastoma--still much to learn.

Authors:  Howard A Fine
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 8.  Tie2: a journey from normal angiogenesis to cancer and beyond.

Authors:  V Martin; D Liu; J Fueyo; C Gomez-Manzano
Journal:  Histol Histopathol       Date:  2008-06       Impact factor: 2.303

9.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

Authors:  Farbod Shojaei; Xiumin Wu; Ajay K Malik; Cuiling Zhong; Megan E Baldwin; Stefanie Schanz; Germaine Fuh; Hans-Peter Gerber; Napoleone Ferrara
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

10.  TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1.

Authors:  Mohammad B Hossain; Rehnuma Shifat; David G Johnson; Mark T Bedford; Konrad R Gabrusiewicz; Nahir Cortes-Santiago; Xuemei Luo; Zhimin Lu; Ravesanker Ezhilarasan; Erik P Sulman; Hong Jiang; Shawn S C Li; Frederick F Lang; Jessica Tyler; Mien-Chie Hung; Juan Fueyo; Candelaria Gomez-Manzano
Journal:  Sci Adv       Date:  2016-04-01       Impact factor: 14.136
View more
  3 in total

Review 1.  Monitoring of tumor vascular normalization: the key points from basic research to clinical application.

Authors:  Wei Li; Ying-Yao Quan; Yong Li; Ligong Lu; Min Cui
Journal:  Cancer Manag Res       Date:  2018-10-03       Impact factor: 3.989

2.  Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity.

Authors:  Su-Nam Jeong; So Young Yoo
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

3.  Tie2-mediated vascular remodeling by ferritin-based protein C nanoparticles confers antitumor and anti-metastatic activities.

Authors:  Young Sun Choi; Hyeonha Jang; Biki Gupta; Ji-Hak Jeong; Yun Ge; Chul Soon Yong; Jong Oh Kim; Jong-Sup Bae; Im-Sook Song; In-San Kim; You Mie Lee
Journal:  J Hematol Oncol       Date:  2020-09-14       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.